Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through studyMarc Ferrante, Luciana Teixeira de Campos, Geert D’Haens et al.|The Lancet|2024Cited by 107
Genome‐wide survey in African Americans demonstrates potential epistasis of fitness in the human genomeHeming Wang, Xiaofeng Zhu, Nathan Morris et al.|Genetic Epidemiology|2016Cited by 13